Clinical Oncology Education

Breakthrough in Precision Oncology: Zidesamtinib Shows Unprecedented Efficacy in ROS1-Positive NSCLC

• Clinical Oncology Education

Breakthrough in Precision Oncology: Zidesamtinib Shows Unprecedented Efficacy in ROS1-Positive NSCLC

Basiran September 22, 2026

Main Facts: A New Frontier in Targeted Lung Cancer Therapy At the 2026 World Conference on Lung...

Read More Read more about Breakthrough in Precision Oncology: Zidesamtinib Shows Unprecedented Efficacy in ROS1-Positive NSCLC

The New Frontier in Blood Cancer: Expert Review of Hematology Calls for Research on Targeted Therapies and ADCs

• Clinical Oncology Education

The New Frontier in Blood Cancer: Expert Review of Hematology Calls for Research on Targeted Therapies and ADCs

Dwi Wanna September 21, 2026

Introduction: A Paradigm Shift in Hematologic Oncology The landscape of oncology is undergoing a seismic shift, moving...

Read More Read more about The New Frontier in Blood Cancer: Expert Review of Hematology Calls for Research on Targeted Therapies and ADCs

Breaking the Silence: New Liquid Biopsy Promises Early Detection for Pancreatic Cancer

• Clinical Oncology Education

Breaking the Silence: New Liquid Biopsy Promises Early Detection for Pancreatic Cancer

Laily UPN September 20, 2026

Pancreatic ductal adenocarcinoma (PDAC) has long been regarded as one of the most formidable challenges in oncology....

Read More Read more about Breaking the Silence: New Liquid Biopsy Promises Early Detection for Pancreatic Cancer

Precision Medicine Breakthrough: Transforming Outcomes for High-Risk Multiple Myeloma Patients

• Clinical Oncology Education

Precision Medicine Breakthrough: Transforming Outcomes for High-Risk Multiple Myeloma Patients

Layla Zulfa September 20, 2026

In a landmark development for oncology, new long-term data from the UK-led OPTIMUM (MUKnine) clinical trial has...

Read More Read more about Precision Medicine Breakthrough: Transforming Outcomes for High-Risk Multiple Myeloma Patients

A Milestone in Oncology: NICE Approves Enhertu for HER2-Low Metastatic Breast Cancer Patients in England

• Clinical Oncology Education

A Milestone in Oncology: NICE Approves Enhertu for HER2-Low Metastatic Breast Cancer Patients in England

Evan Lee Salim September 19, 2026

In a landmark decision that promises to reshape the standard of care for thousands of patients, the...

Read More Read more about A Milestone in Oncology: NICE Approves Enhertu for HER2-Low Metastatic Breast Cancer Patients in England

A Paradigm Shift in Thoracic Oncology: DESTINY-Lung04 Trial Positions T-DXd as a New Standard for HER2-Mutant NSCLC

• Clinical Oncology Education

A Paradigm Shift in Thoracic Oncology: DESTINY-Lung04 Trial Positions T-DXd as a New Standard for HER2-Mutant NSCLC

Neng Nana September 19, 2026

In a landmark development for thoracic oncology, the primary results of the Phase III DESTINY-Lung04 trial have...

Read More Read more about A Paradigm Shift in Thoracic Oncology: DESTINY-Lung04 Trial Positions T-DXd as a New Standard for HER2-Mutant NSCLC

The Hidden Toll: Unmasking How Childhood Chemotherapy Affects Healthy Tissue

• Clinical Oncology Education

The Hidden Toll: Unmasking How Childhood Chemotherapy Affects Healthy Tissue

Asro September 19, 2026

For decades, the survival rates for childhood cancer have been a triumph of modern medicine. Platinum-based chemotherapy...

Read More Read more about The Hidden Toll: Unmasking How Childhood Chemotherapy Affects Healthy Tissue

Precision Oncology in Renal Cell Carcinoma: Exploring Adaptive Treatment Strategies with Pembrolizumab and Axitinib

• Clinical Oncology Education

Precision Oncology in Renal Cell Carcinoma: Exploring Adaptive Treatment Strategies with Pembrolizumab and Axitinib

Nana Wu September 18, 2026

The landscape of renal cell carcinoma (RCC) treatment is undergoing a fundamental transformation. As clinicians move away...

Read More Read more about Precision Oncology in Renal Cell Carcinoma: Exploring Adaptive Treatment Strategies with Pembrolizumab and Axitinib

Targeted Protein Degradation: Taylor & Francis Announces Call for Papers on the Future of PROTACs in Epigenomics

• Clinical Oncology Education

Targeted Protein Degradation: Taylor & Francis Announces Call for Papers on the Future of PROTACs in Epigenomics

Lina Irawan September 16, 2026

In a significant move to consolidate the rapidly evolving field of targeted protein degradation, the prestigious academic...

Read More Read more about Targeted Protein Degradation: Taylor & Francis Announces Call for Papers on the Future of PROTACs in Epigenomics

Bridging the Stromal Gap: Advancing Tumor Microenvironment Modeling via Synthetic CAF Induction

• Clinical Oncology Education

Bridging the Stromal Gap: Advancing Tumor Microenvironment Modeling via Synthetic CAF Induction

Jia Lissa September 16, 2026

Date: November 5, 2026 Time: 07:00 PST | 10:00 EST | 15:00 GMT The complexities of the...

Read More Read more about Bridging the Stromal Gap: Advancing Tumor Microenvironment Modeling via Synthetic CAF Induction